Page last updated: 2024-10-30

leflunomide and Carcinoma, Non-Small Cell Lung

leflunomide has been researched along with Carcinoma, Non-Small Cell Lung in 1 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jiang, L1
Zhang, W1
Li, W1
Ling, C1
Jiang, M1

Other Studies

1 other study available for leflunomide and Carcinoma, Non-Small Cell Lung

ArticleYear
Anti-inflammatory drug, leflunomide and its metabolite teriflunomide inhibit NSCLC proliferation in vivo and in vitro.
    Toxicology letters, 2018, Jan-05, Volume: 282

    Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung;

2018